NurExone Biologic EBIT

The latest EBIT for NRX.V is $-6.3M as of June 2026. That compares with $-6.2M in the prior-year period — down 1.1% year over year. That is below the Healthcare sector average of $22B. Investors often review this figure alongside NurExone Biologic's historical trend and sector peers before judging valuation or financial health.

Over the past year, NRX.V's EBIT moved from $-6.2M to $-6.3M — a 1.1% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in NurExone Biologic's operating scale or balance-sheet position.

Against Healthcare companies, NRX.V currently prints $-6.3M for EBIT, while the sector average sits near $22B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at NurExone Biologic's growth, margins, and balance sheet.

A EBIT figure of $-6.3M for NRX.V is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $22B. Explore the charts below for those layers of context.

After noting NRX.V's EBIT ($-6.3M), review year-over-year change from $-6.2M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.